Mechanism of synergistic enhancement of 𝛼-secretase (ADAM10) activity by EGCG and FA

Abstract

Enhancing the activity of 𝛼-secretase has emerged as a potential therapeutic strategy for treating Alzheimer’s disease (AD). The exploration of small molecules that can enhance 𝛼-secretase activity and their mechanisms provides insights for future AD treatments and the development of novel activators. In this study, ADAM10, a major 𝛼-secretase, is used as a model and is bound with the ligands (− )-epigallocatechin-3-gallate (EGCG) and ferulic acid (FA) in a 1:2 ratio (ADAM10:EGCG/FA = 1:2/2) and equimolar ratio (ADAM10:EGCG:FA = 1:1:1) to investigate the effects on ADAM10 activation and reveal the synergistic mechanism of the EGCG and FA combination. The activity of ADAM10 was enhanced by the combination of EGCG and FA, compared to that achieved with EGCG or FA alone, where EGCG plays a dominant role, whereas FA plays a supportive role. The combined use of EGCG induces strong hydrophobic interactions between ADAM10 and FA, causing FA to dissociate from the S1 domain, thereby preventing the inhibition of ADAM10 activity by pure FA. The presence of FA allows EGCG to bind more precisely within the active cavity of ADAM10, thereby increasing the binding strength. Overall, the combination of EGCG and FA significantly increased the distance between the S1 domain and the cysteine-rich C-terminus, further opening up the cavity containing the active sites, consequently exposing more active sites and enhancing the activity of ADAM10.

Keywords

ADAM10 / EGCG / FA / Synergistic mechanism / Increased activity

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

CRediT authorship contribution statement

Yvning Guan: Writing – original draft, Visualization, Validation, Investigation, Formal analysis, Data curation, Conceptualization. Wen Xu: Validation, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Hongqi Ai: Writing – review & editing, Supervision, Resources, Project administration, Funding acquisition, Conceptualization.

Acknowledgements

This study was supported by the Natural Science Foundation of Shandong Province, China (Grant No.: ZR2022MB073 ).

References

[1] A.P. Huovila, A.J. Turner, M. Pelto-Huikko, I. Kärkkäinen, R.M. Ortiz, Shedding light on ADAM metalloproteinases, Trends Biochem. Sci. 30 (2005) 413-422, doi: 10.1016/j.tibs.2005.05.006.

[2] J.C. Aster, W.S. Pear, S.C. Blacklow, The varied roles of notch in cancer, Annu. Rev. Pathol. 12 (2017) 245-275, doi: 10.1146/annurev-pathol-052016-100127.

[3] J. Ellen, P. Johannes, B. Christian, W. Silvio, S. Ralf, S. Lutgarde, S. An, C. Katleen, T. Amantha, T. Ina, B. Udo, W. Gisela, P.B. Carl, G. Markus, S. Bart De, S. Paul, The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex, J. Neurosci. 30 (2010) 4833, doi: 10.1523/JNEUROSCI.5221-09.2010.

[4] R. Peron, I.P. Vatanabe, P.R. Manzine, A. Camins, M.R. Cominetti, Alpha-secretase ADAM10 regulation: Insights into Alzheimer’s disease treatment, Pharmaceuticals (Basel) 11 (2018) 12, doi: 10.3390/ph11010012.

[5] P.H. Kuhn, H. Wang, B. Dislich, A. Colombo, U. Zeitschel, J.W. Ellwart, E. Kremmer, S. Roßner, S.F. Lichtenthaler, ADAM10 is the physiologically relevant, constitutive 𝛼-secretase of the amyloid precursor protein in primary neurons , EMBO J. 29 (2010) 3020-3032, doi: 10.1038/emboj.2010.167.

[6] M.P. Oliveira Monteiro e Pereira de Almeida, R. Valle Pedroso, M. Mantellato Grigoli, T. Vicente Silva, P.R. Manzine, M.R. Cominetti, ADAM10 as a biomarker for Alzheimer’s disease: A systematic review, Rev. Neurol. (Paris) 180 (2024) 1-11, doi: 10.1016/j.neurol.2023.04.002.

[7] C.B. Abraham, L. Xu, G.A. Pantelopulos, J.E. Straub, Characterizing the transmembrane domains of ADAM10 and BACE1 and the impact of membrane composition, Biophys. J. 122 (2023) 3999-4010, doi: 10.1016/j.bpj.2023.08.025.

[8] J. Suh, S.H. Choi, D.M. Romano, M.A. Gannon, A.N. Lesinski, D.Y. Kim, R.E. Tanzi, ADAM10 missense mutations potentiate 𝛽-amyloid accumulation by impairing prodomain chaperone function , Neuron 80 (2013) 385-401, doi: 10.1016/j.neuron.2013.08.035.

[9] R. Postina, A. Schroeder, I. Dewachter, J. Bohl, U. Schmitt, E. Kojiro, C. Prinzen, K. Endres, C. Hiemke, M. Blessing, P. Flamez, A. Dequenne, E. Godaux, F. Van Leuven, F. Fahrenholz, A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model, J. Clin. Invest. 114 (2004) 598- 598, doi: 10.1172/JCI20864E1.

[10] R. Yan, R. Vassar, Targeting the 𝛽 secretase BACE1 for Alzheimer’s disease therapy , Lancet Neurol. 13 (2014) 319-329, doi: 10.1016/S1474-4422(13)70276-X.

[11] T.C.M. Seegar, L.B. Killingsworth, N. Saha, P.A. Meyer, D. Patra, B. Zimmerman, P.W. Janes, E. Rubinstein, D.B. Nikolov, G. Skiniotis, A.C. Kruse, S.C. Blacklow, Structural basis for regulated proteolysis by the 𝛼-secretase ADAM10 , Cell 171 (2017) 1638-1648, doi: 10.1016/j.cell.2017.11.014.

[12] J. Cummings, G. Lee, P. Nahed, M. Kambar, K. Zhong, J. Fonseca, K. Taghva, Alzheimer’s disease drug development pipeline: 2022, Alzheimer’s Dementia (New York, N. Y.) 8 (2022) e12295, doi: 10.1002/trc2.12295.

[13] R.-Z. Kavon, S. Doug, S. Nan, M. Takashi, H. Huayan, J. Deborah, E. Jared, T. Kirk, Z. Jin, M. David, H. John, T. Terrence, T. Jun, Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice, J. Neurosci. 25 (2005) 8807, doi: 10.1523/JNEUROSCI.1521-05.2005.

[14] A. Chowdhury, J. Sarkar, T. Chakraborti, P.K. Pramanik, S. Chakraborti, Protective role of epigallocatechin-3-gallate in health and disease: A perspective, Biomed. Pharmacother. 78 (2016) 50-59, doi: 10.1016/j.biopha.2015.12.013.

[15] T. Mori, N. Koyama, J. Tan, T. Segawa, M. Maeda, T. Town, Combined treatment with the phenolics (-)-epigallocatechin-3-gallate and ferulic acid improves cognition and reduces Alzheimer-like pathology in mice, J. Biol. Chem. 294 (2019) 2714-2731, doi: 10.1074/jbc.RA118.004280.

[16] T.L. Young-Pearse, A.C. Chen, R. Chang, C. Marquez, D.J. Selkoe, Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1, Neural Dev. 3 (2008) 15, doi: 10.1186/1749-8104-3-15.

[17] D. Kaden, L.M. Munter, M. Joshi, C. Treiber, C. Weise, T. Bethge, P. Voigt, M. Schaefer, M. Beyermann, B. Reif, G. Multhaup, Homophilic interactions of the amyloid precursor protein (APP) ectodomain are regulated by the loop region and affect 𝛽-secretase cleavage of APP^∗ , J. Biol. Chem. 283 (2008) 7271-7279, doi: 10.1074/jbc.M708046200.

[18] R. Ahmed, B. Vanschouwen, N. Jafari, X. Ni, J. Ortega, G. Melacini, Molecular mechanism for the (− )-epigallocatechin gallate-induced toxic to nontoxic remodeling of A 𝛽 oligomers , J. Am. Chem. Soc. 139 (2017) 13720-13734, doi: 10.1021/jacs.7b05012.

[19] R. Ahmed, M. Akcan, A. Khondker, M.C. Rheinstädter, J.C. Bozelli, R.M. Epand, V. Huynh, R.G. Wylie, S. Boulton, J. Huang, C.P. Verschoor, G. Melacini, Atomic resolution map of the soluble amyloid beta assembly toxic surfaces, Chem. Sci. 10 (2019) 6072-6082, doi: 10.1039/C9SC01331H.

[20] K. Martinez Pomier, R. Ahmed, G. Melacini, Catechins as tools to understand the molecular basis of neurodegeneration, Molecules 25 (2020) 3571, doi: 10.3390/molecules25163571.

[21] N. Kumar, V. Pruthi, Potential applications of ferulic acid from natural sources, Biotechnol 4 (2014) 86-93, doi: 10.1016/j.btre.2014.09.002.

[22] S. Mathew, T.E. Abraham, Ferulic acid: An antioxidant found naturally in plant cell walls and feruloyl esterases involved in its release and their applications, Crit. Rev. Biotechnol. 24 (2004) 59-83, doi: 10.1080/07388550490491467.

[23] B.G. Smith, P.J. Harris, Ferulic acid is esterified to glucuronoarabinoxylans in pineapple cell walls, Phytochemistry 56 (2001) 513-519, doi: 10.1016/S0031-9422(00)00401-5.

[24] K. Ono, M. Hirohata, M. Yamada, Ferulic acid destabilizes preformed 𝛽-amyloid fibrils in vitro , Biochem. Biophys. Res. Commun. 336 (2005) 444-449, doi: 10.1016/j.bbrc.2005.08.148.

[25] T. Mori, N. Koyama, M.V. Guillot-Sestier, J. Tan, T. Town, Ferulic acid is a nutraceutical 𝛽-secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice , PLoS One 8 (2013) e55774, doi: 10.1371/journal.pone.0055774.

[26] A. Bumrungpert, S. Lilitchan, S. Tuntipopipat, N. Tirawanchai, S. Komindr, Ferulic acid supplementation improves lipid profiles, oxidative stress, and inflammatory status in hyperlipidemic subjects: A randomized, double-blind, placebo-controlled clinical trial, Nutrients 10 (2018) 713, doi: 10.3390/nu10060713.

[27] T. Mori, N. Koyama, J. Tan, T. Segawa, M. Maeda, T. Town, Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer’s disease, J. Biol. Chem. 292 (2017) 11310-11325, doi: 10.1074/jbc.M116.762658.

[28] I. Hussain, J. Hawkins, D. Harrison, C. Hille, G. Wayne, L. Cutler, T. Buck, D. Walter, E. Demont, C. Howes, A. Naylor, P. Jeffrey, M.I. Gonzalez, C. Dingwall, A. Michel, S. Redshaw, J.B. Davis, Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo, J. Neurochem. 100 (2007) 802-809, doi: 10.1111/j.1471-4159.2006.04260.x.

[29] D.F. Obregon, K. Rezai-Zadeh, Y. Bai, N. Sun, H. Hou, J. Ehrhart, J. Zeng, T. Mori, G.W. Arendash, D. Shytle, T. Town, J. Tan, ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein, J. Biol. Chem. 281 (2006) 16419-16427, doi: 10.1074/jbc.M600617200.

[30] G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A.J. Olson, AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility, J. Comput. Chem. 30 (2009) 2785-2791, doi: 10.1002/jcc.21256.

[31] G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, A.J. Olson, Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function, J. Comput. Chem. 19 (1998) 1639-1662, doi: 10.1002/(SICI)1096-987X(19981115)19:14 < 1639::AID-JCC10 >3.0.CO;2-B.

[32] Z. Zsoldos, D. Reid, A. Simon, B.S. Sadjad, A.P. Johnson, eHiTS: An innovative approach to the docking and scoring function problems, Curr. Protein Pept. Sci. 7 (2006) 421-435, doi: 10.2174/138920306778559412.

[33] W. Jorgensen, J. Chandrasekhar, J. Madura, R. Impey, M. Klein, Comparison of simple potential functions for simulating liquid water, J. Chem. Phys. 79 (1983) 926-935, doi: 10.1063/1.445869.

[34] S.K. Mudedla, N.A. Murugan, H. Agren, Effect of familial mutations on the interconversion of alpha-helix to beta-sheet structures in an amyloid-forming peptide: Insight from umbrella sampling simulations, ACS Chem. Neurosci. 10 (2019) 1347-1354, doi: 10.1021/acschemneuro.8b00425.

[35] T. Darden, D. York, L. Pedersen, Particle mesh Ewald: An N-log(N) method for Ewald sums in large systems, J. Chem. Phys. 98 (1993) 10089-10092, doi: 10.1063/1.464397.

[36] B. Hess, H. Bekker, H.J.C. Berendsen, J.G.E.M. Fraaije, LINCS: A linear constraint solver for molecular simulations, J. Comput. Chem. 18 (1997) 1463-1472, doi: 10.1002/(SICI)1096-987X(199709)18:12 < 1463::AID-JCC4 >3.0.CO;2-H.

[37] W.G. Hoover, Canonical dynamics: Equilibrium phase-space distributions, Phys. Rev. 31 (1985) 1695-1697, doi: 10.1103/PhysRevA.31.1695.

[38] H.J.C. Berendsen, J.P.M. Postma, W.F. Van Gunsteren, A. Dinola, J.R. Haak, Molecular dynamics with coupling to an external bath, J. Chem. Phys. 81 (1984) 3684-3690, doi: 10.1063/1.448118.

[39] M.J. Frisch, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G.A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H.P. Hratchian, A.F. Izmaylov, J. Bloino, G. Zheng, J.L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J.A. Montgomery Jr., J.E. Peralta, F. Ogliaro, M.J. Bearpark, J. Heyd, E.N. Brothers, K.N. Kudin, V.N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A.P. Rendell, J.C. Burant, S.S. Iyengar, J. Tomasi, M. Cossi, N. Rega, N.J. Millam, M. Klene, J.E. Knox, J.B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R.E. Stratmann, O. Yazyev, A.J. Austin, R. Cammi, C. Pomelli, J.W. Ochterski, R.L. Martin, K. Morokuma, V.G. Zakrzewski, G.A. Voth, P. Salvador, J.J. Dannenberg, S. Dapprich, A.D. Daniels, Ö. Farkas, J.B. Foresman, J.V. Ortiz, J. Cioslowski, D.J.. Fox, Gaussian 09, Gaussian, Inc., Wallingford, CT, 2009 Gaussian09.

[40] S. Jo, T. Kim, V.G. Iyer, W. Im, CHARMM-GUI: A web-based graphical user interface for CHARMM, J. Comput. Chem. 29 (2008) 1859-1865, doi: 10.1002/jcc.20945.

[41] J. Lee, X. Cheng, J.M. Swails, M.S. Yeom, P.K. Eastman, J.A. Lemkul, S. Wei, J. Buckner, J.C. Jeong, Y. Qi, S. Jo, V.S. Pande, D.A. Case, C.L. Brooks 3rd, A.D. Mackerell Jr., J.B. Klauda, W. Im, CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field, J. Chem. Theory Comput. 12 (2016) 405-413, doi: 10.1021/acs.jctc.5b00935.

[42] R. Kumari, R. Kumar, A. Lynn, g_mmpbsa -A GROMACS tool for high-throughput MM-PBSA calculations, J. Chem. Inf. Model. 54 (2014) 1951-1962, doi: 10.1021/ci500020m.

[43] L.M. Espinoza-Fonseca, Molecular docking of four 𝛽-amyloid1-42 fragments on the 𝛼7 nicotinic receptor: Delineating the binding site of the A 𝛽 peptides , Biochem. Biophys. Res. Commun. 323 (2004) 1191-1196, doi: 10.1016/j.bbrc.2004.08.218.